

Research

Evaluation of high performance liquid chromatography (HPLC) pattern and prevalence of beta-thalassaemia trait among sickle cell disease patients in Lagos, Nigeria

Titilope Adeyemo^{1,*}, Oyesola Ojewunmi², Ajoke Oyetunji²

¹Department of Haematology and Blood transfusion, College of Medicine, University of Lagos, P.M.B 12003, Surulere, Lagos, Nigeria, ²National Sickle Cell Centre, Surulere, Lagos, Nigeria

*Corresponding author: Titilope Adeyemo, Department of Haematology and Blood transfusion, College of Medicine, University of Lagos, Lagos, Nigeria

Key words: Sickle cell disease, thalassaemia, microcytosis, HPLC, haemoglobin variants, foetal haemoglobin, Nigerian patients, hypochromia

Received: 22/03/2014 - Accepted: 14/05/2014 - Published: 22/05/2014

Abstract

Introduction: Sickle cell disease (SCD) is the most common inherited disorder of haemoglobin worldwide. This study evaluated the chromatographic patterns and red blood cell indices of sickle cell patients to determine the co-inheritance of other haemoglobin(Hb) variants and β -thalassaemia trait. **Methods:** Red cell indices, blood film, sickle solubility test, Hb electrophoresis using alkaline cellulose acetate membrane, and chromatographic patterns using Bio Rad HPLC Variant II were evaluated for 180 subjects. **Results:** Based on low MCV <76fl and MCH<25 pg, in the presence of elevated Hb A₂ (>4.0%) on HPLC and Hb variants eluting outside the S and C windows, at least four haemoglobin phenotypes (SS: 87.7%; SC: 1.1%; SD Punjab: 0.6%; S β -thalassemia: 10.6%) were identified. Mean Hb F% was 8.1 \pm 5.1 (median 7.65) for Hb SS and 6.03 \pm 5.2 (median 3.9) for Hb S β -thalassemia trait. Majority of Hb SS (69.1%) had Hb F% less than 10 while 27.6% had 10-19.9 and 3.2% had \geq 20. Mean Hb F% was higher in female Hb SS (9.55 \pm 5.09; mean age 7.4 \pm 3.8 years) than the males (7.63 \pm 4.80; mean age 6.9 \pm 3.8 years) (P=0.02). A borderline significant negative correlation between age and Hb F levels among Hb SS subjects (r= -0.169 P=0.038) was also observed. **Conclusion:** Our results suggest that α and β - thalassaemia traits, and other haemoglobin variants co-exist frequently with SCD in our populationn

Pan African Medical Journal. 2014; 18:71 doi:10.11604/pamj.2014.18.71.4239

This article is available online at: <http://www.panafrican-med-journal.com/content/article/18/71/full/>

© Titilope Adeyemo et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Haemoglobinopathies are inherited disorders characterised by either an abnormality in the structure of haemoglobin such as in sickle cell anaemia or reduced production of one or more globin chains in thalassaemia [1]. The latter is generally classified into two: alpha thalassaemia - usually caused by deletions of one or both of the duplicated α - genes and beta thalassaemia which is typically caused by a point mutation in one of the β -globin genes resulting in a reduced or absent β -globin chain synthesis [2]. Sickle cell disease (SCD) is the most common, accounting for about 70% of the world's major haemoglobinopathies [3]. It comprises of sickle cell anaemia and other compound heterozygous state such as haemoglobin SC disease, S β -thalassaemia, and SD-Punjab. About 5% of the world's populations are carriers of genes responsible for haemoglobinopathies and about 300,000 children are born annually with haemoglobin disorders. Approximately 70% of these cases occur in sub-Saharan Africa [4]. Due to the high prevalence of sickle cell trait at 23.7%, the frequency of sickle cell anaemia in Nigeria is about 20 per 1000 births resulting in about 150,000 babies being born each year with the disorder [4]. This makes Nigeria the country with the largest burden of sickle cell disease globally with 4.1% of the population being affected [5]. Current methods used by laboratories in the evaluation of haemoglobin disorders include sickle solubility test, alkaline and acid electrophoresis, isoelectric focusing (IEF), high performance liquid chromatography (HPLC), capillary electrophoresis, globin chain electrophoresis and DNA analysis/protein analysis [2]. However, it is important to stress that in conjunction with any of these methods, evaluation of the peripheral blood smear, as well as correlation with the results of a full blood count (FBC) are very important as many of the clinically significant haemoglobin disorders show characteristic peripheral blood findings, and are often co-inherited. This present study evaluated the high performance liquid chromatographic patterns and red cell indices of sickle cell disease patients to determine the co-inheritance of other haemoglobin (Hb) variants and β -thalassaemia traits in SCD patients in Nigeria.

Methods

Patients and clinical procedures :

This was a prospective study of 180 Sickle cell disease (SCD) patients in steady state who presented at the haemoglobin reference laboratory of National Sickle Cell Centre, Lagos, Nigeria. Patients on hydroxyurea and those who have had blood transfusion at most four months prior to recruitment for the study were excluded. Ethical approval was granted by the Health Research Ethics Committee of the Lagos University Teaching Hospital, Lagos, Nigeria. 5 ml venous blood sample was collected into EDTA anticoagulant bottles after obtaining written informed consent from parents/guardians.

Laboratory Procedures:

Red cell indices were evaluated using an automated haematology analyser (Mindray, BC-2800). Microcytic, hypochromic anaemia is pivotal to diagnosis of β -thalassaemia trait with MCV and Hb A₂ being significant diagnostic elements [6]. In this study, subjects with MCV<76fl and MCH<25pg, in the presence of elevated Hb A₂ (>4.0%) on HPLC were presumed to have S β -thalassaemia trait while

those with Hb A₂ <3.5% and borderline Hb A₂ (<3.5-4.0%) with MCV<76fl and MCH<25pg are presumed to have either an iron deficiency or a co-existing α -thalassaemia [7].

Solubility test was performed by standard method as described by Dacie and Lewis and conducted with both positive and negative controls. The presence of a red precipitate indicated Hb S [8]. Cellulose acetate electrophoresis was done on samples and controls also by standard methods as described by Dacie and Lewis. Blood smear was stained with Leishman's stain and examined microscopically for morphology of the red cells [8]. High Performance Liquid Chromatograph of samples was carried out using Bio-Rad Laboratories, Hercules, CA. The chromatographic patterns were evaluated for the identification and quantification of different Hb variants. Each haemoglobin variant has its characteristic retention time. Retention time is the elapsed time from the sample injection to the apex of a haemoglobin peak. The "windows" are established ranges in which common variants have been observed to elute using the Variant beta - thalassaemia short program. The printed chromatogram shows all the haemoglobin variants eluted, the retention times, the areas of the peaks and the values (%) of different haemoglobin components. If a peak eluted at a retention time that is not pre-defined, it is labelled as an unknown.

Statistical analysis:

Data was analyzed using SPSS version 21 (IBM Inc.) and presented as mean \pm standard deviation. Independent student's t-test was used to compare means of two variables while one-way ANOVA was used to compare mean difference among three variables. Pearson correlation was used to test the relationship between variables. P-value

Results

The mean age of the 180 study participants was 7.08 \pm 3.81 years, median 6.0 years and age range 2-15 years. There were 70 females (38.9%) to 110 males (61.1%). The Solubility test was positive for all samples confirming the presence of haemoglobin S. Haemoglobin electrophoresis showed 178 (98.9%) of the patients are homozygous for Hb S and 2 (1.1%) were heterozygous for SC. However, using the high performance liquid chromatographic patterns and HbA₂ levels >4.0% and red cell indices (MCV<76fl, MCH<25pg), four haemoglobin phenotypes; 158 Hb SS (87.7%); 2 Hb SC (1.1%); 1 SD-Punjab (0.6%) and 19 S β -thalassaemia trait (10.6%) were identified in this study. **Table 1** shows HPLC patterns and red cell indices of the study participants. The mean MCV and MCH in S β -thalassaemia trait (69.7 \pm 5.3, 21.6 \pm 1.7) were significantly lower ($P<0.05$) than Hb SS (79.2 \pm 8.1, 28.4 \pm 2.6). Mean Hb A₂ of S β -thalassaemia trait (5.14 \pm 1.3) was also significantly higher ($P<0.05$) than Hb SS (3.76 \pm 2.53). Mean Hb F% was 8.1 \pm 5.1 (median 7.65; range 1.2-25.5%) for Hb SS and 6.03 \pm 5.2 (median 3.9, range 1-21.4%) for Hb S β -thalassaemia trait. Mean HbF% was higher in female Hb SS (9.55 \pm 5.09; mean age 7.4 \pm 3.8 years) than the males (7.63 \pm 4.80; mean age 6.9 \pm 3.8 years) ($P<0.05$). So is Hb A₂ significantly higher in females than in male Hb SS. Patients with S β -thalassaemia trait did not show any significant differences in HbF% and HbA₂% between the sexes (**Table 2**). Higher values of Hb F% were observed in children aged less than 5 years (9.23 \pm 5.3), but no statistical difference was observed between the

different age groups (Table 3). Hb F% in S β -thalassaemia trait reduces significantly with age (Table 3).

We observed a borderline significant negative correlation between age and Hb F levels among Hb SS subjects ($r = -0.169$, $P = 0.038$). HbA₂ did not show any significant difference with age in Hb SS and S β -thalassaemia trait. Majority of Hb SS (69.1%) had HbF% less than 10 while 27.6% had 10-19.9 and 3.2% had ≥ 20 . Association between foetal haemoglobin distribution and age among Hb SS as shown in Table 4 did not show any significance ($P = 0.889$). Thirty-five of 158 Hb SS (22.1%) had $MCV < 76$ fl (mean 69.87 ± 5.37) compared to the mean MCV (83.30 ± 5.01) of the other 123 Hb SS; 29 of the former had normal HbA₂% (mean 2.81 ± 1.38) while the remaining 6 had borderline HbA₂ (3.5-4.0%) which is suggestive of $\delta\beta$ thalassaemia.

Discussion

Haematological characteristics and clinical severity of SCD are heterogeneous and are associated with environmental and genetic factors that include variation in HbF level, the haplotype locale that is linked to the β -globin gene and the co-inheritance of α -thalassaemia and other Hb variants [9]. Full blood count and the red cell indices are essential in the preliminary investigation of haemoglobinopathies. Though cellulose electrophoresis at alkaline pH is highly reproducible and is able to separate haemoglobin variants within a very short time, it cannot be used to separate Hb S, Hb D, and Hb G at this pH because they co-migrate. Hb A₂, Hb C, Hb E, and Hb O-Arab also co-migrate at alkaline pH. Sick cell solubility test detects the presence of haemoglobin S by precipitation of the insoluble haemoglobin variant creating a cloudy, turbid suspension in a prepared test solution. One sample showed a positive solubility test like the AS control but on cellulose acetate electrophoresis at alkaline pH, showed only one band in the S region. However, the chromatographic pattern for co-inheritance of Hb S and D was clearly shown. This Hb variant and its co-inheritance with Hb S are rare but present in Nigerian population. Hb D is seen in blacks and people from India and sporadically in other races. Therefore, accurate diagnosis of haemoglobinopathies which has implications for genetic counselling cannot be overemphasized in Nigeria.

The Mean MCV reported in this present study among Hb SS patients is in agreement with Omoti and Akinbami et al., who reported 79.2 fL and 81.52 fL respectively [10,11]. Mean MCV , MCH , and $MCHC$ were significantly reduced ($P < 0.05$) in patients with β -thalassaemia trait compared to the Hb SS patients (Table 1). The ranges of MCV , MCH , and Hb A₂ observed in this study are in agreement with what Old described for carriers of β -thalassaemia [12]. Several studies have shown that the complement of $MCH < 27$ pg with $MCV < 78$ fl increases the risk of thalassaemia and have shown the reliability and suitability of using these red cell indices in the laboratory screening for thalassaemia [11-13]. Quantitative evaluation of Hb A₂ by elution, spectrophotometry or densitometric scanning after cellulose acetate electrophoresis or micro-column chromatography is not always precise [14]. HPLC has replaced alkaline electrophoresis as the primary screening method of haemoglobinopathies. The reliability and reproducibility of results has made HPLC the method of choice for quantifying Hb F and Hb A₂ for laboratory diagnosis of haemoglobinopathies [15]. Elevated HbA₂ is the most significant parameter in the identification of β -thalassaemia carriers. However, in some cases, the level of HbA₂ is not typically elevated and some difficulties may arise in making the diagnosis. For these reasons, the quantification of HbA₂ has to be performed with great accuracy and the result interpreted together with other haematological and biochemical parameters [7]. This is also difficult in the presence of

Hb S when HbA₂ measured by HPLC is often elevated because of co-elution with glycated Hb S [16]. However, when Hb S variant is present, and Hb A is reduced or absent, percentage Hb A₂, Hb F, and FBC parameters may be useful for distinguishing between homozygosis for Hb S and combination of Hb S and β -thalassaemia (hemizygosis) [17].

Phenotypic heterogeneity of sickle cell disease is strongly modulated by foetal haemoglobin [18]. Reduced rate of acute painful episodes, leg ulcers, osteonecrosis, acute chest syndromes, and reduced disease severity have all been associated with elevated levels of Hb F while the association of complications like stroke and priapism with Hb F is unclear [19]. These could point to the fact that Hb F levels are influenced by β -globin haplotypes and genetic polymorphisms. For instance, Senegal and Arab-Indian haplotypes usually have the highest Hb F and mildest clinical presentations while Bantu haplotypes have the lowest Hb F and most severe clinical course; Benin haplotypes have intermediate levels of Hb F and moderate clinical course [20]. Varied foetal haemoglobin levels (2-9%) have been reported from different studies involving sickle cell patients in Nigeria [21-25]. The mean (\pm SD) HbF level of $8.05 \pm 5.07\%$, range 0.4 - 25.5% in our Hb SS population is comparable to that of previous studies in Nigeria which reported means ranging from 7.4 - 9.5% [24,25]. We suspect that discrepancies in the foetal haemoglobin levels estimated in Nigerian Sick cell patients may be the consequence of method used in the various studies. For instance, alkali denaturation method of Hb F estimation may be subject to under estimation [14]. Studies from Congo, Uganda, and Saudi Arabia had reported 8.8 %, 9.0% and 9.1% respectively [26,27]. In our study, mean Hb F level was higher in Hb SS females than males with statistical significance ($P = 0.02$). This is supported by other studies [21, 26, 28,29]. It is not consistent with other studies that reported higher Hb F level in males than in females although with no statistical significance [22, 24]. It was surmised that hormonal effects of puberty might account for the difference observed in Hb F levels between females and males [28]. We observed a significant negative correlation between age and HbF levels among Hb SS subjects ($r = -0.169$, $P = 0.038$). This is in agreement with the study of Olatunji [30]. We reported a higher proportion of subjects with elevated Hb F levels (32.3%) than a previous study in Nigeria (17%) but lower than what was reported from Uganda [25, 31]. Mean Hb A₂ concentration observed among Hb SS patients in this study is higher than 2.4% reported by Fatunde and Scott-Emuakpor [25]. Falsely elevated levels of Hb A₂ in the presence of Hb S when HPLC is employed may be responsible for this difference. Meanwhile, our mean Hb A₂ is lower than 4.52% reported in another Nigerian study [10]. This higher value may suggest co-existing β -thalassaemia trait among the sickle cell population studied.

β -thalassaemia is predominantly found in the Mediterranean countries, the Middle East, Central Asia, India, North Coast of Africa and South America [32]. People with β -thalassaemia trait are usually clinically asymptomatic but sometimes have a mild anaemia [32]. About 10.6% of our study subjects had HbA₂ $> 4.0\%$ in the presence of microcytosis and hypochromia suggesting a co-existing β -thalassaemia. This is a much higher prevalence compared to that reported in previous studies [10, 33]. This could be because previous studies had used either only HbA₂ level ($< 3.5\%$) or red cell indices alone to estimate the carrier frequency of the β -thalassaemia gene which is subject to underestimation. Nevertheless, prevalence of β -thalassaemia trait in a Nigerian population with Hb AA which revealed 24% may lend credence to S β -thalassaemia trait reported in this study [34]. The method for HbA₂ estimation in this study (HPLC) uses a cutoff of HbA₂ $> 4.0\%$ in contrast to previous studies that used a cut off value of $> 3.5\%$. To the best of our knowledge, this is the first time HPLC is reported in

Nigeria as a primary screening for haemoglobinopathies. Although the presence of α -thalassaemia, commonly found in malaria endemic regions is of little clinical significance in Nigeria, predominance of α +thalassaemia (commonly $-\alpha^{3,7}$ deletion) in West African general population is quite known with prevalence of 45.5% from South-West Nigeria and 36-37% from two separate studies conducted in Ghana [35-37]. α -thalassaemia carriers are usually asymptomatic but can be slightly anaemic, microcytic and hypochromic. Co-inheritance of α -thalassaemia with Hb SS would also be present in the Nigerian population; this may show red cell indices with similar representation of β -thalassaemia trait [34] but when there is reduced/normal Hb A₂ with reduced MCV and MCH with elevated Hb F (3-16%), $\delta\beta$ or $\gamma\delta\beta$ thalassaemia may be present [14].

The distribution, clinical presentations, and haematological features of haemoglobinopathies in Nigeria have been previously investigated. In Nigeria, a resource limited country, evaluation of haemoglobinopathy is mostly limited to sickling/solubility test and alkaline electrophoresis. This unarguably underscores inaccurate diagnosis and limits our knowledge of the Hb variants present in our population. Therefore, it becomes imperative that evaluation of the peripheral blood smear, and red cell indices as well as confirmation of haemoglobin variant by alternative methods are very important in the diagnosis of sickle cell disease. This will provide accurate information for genetic risk assessment and counseling and adequate management of SCD.

Conclusion

Our results suggest that α -thalassaemia, β -thalassaemia, and other Hb variants co-exist frequently with SCD in our population. Thus, presumptive diagnosis of haemoglobinopathy in Nigeria should transcend routine alkaline electrophoresis and solubility test and should include evaluation of full blood count, red cell indices, iron studies and HPLC as a method suited for the identification and quantification of other Hb variants while DNA analysis for definitive diagnosis will be good to have. The prevalence of S β -thalassaemia trait reported in this study is presumptive; a definitive study in a large cross-sectional study will be worthwhile

Competing interests

The authors declare no competing interests.

Authors' contributions

Titilope Adeyemo conceived and designed the study, and participated in the laboratory analysis and interpretation of results. Oyesola Ojewunmi participated in the study design, recruited the patients, performed the statistical analysis, and wrote the first draft of the manuscript. Ajoke Oyetunji participated in the patients' recruitment and laboratory analysis, and interpretation of results. All authors have read and approved the final manuscript.

Acknowledgments

We would like to say a big thank you to Chris Lambert and the team in Red Cell Laboratory at King's College Hospital, London for the laboratory assistance and Yemi Onijala for sample collection.

Tables

Table 1: Haemoglobin chromatographic pattern and red cell indices

Table 2: HbF% and HbA₂ according to sex

Table 3: HbF% and A₂ according to age

Table 4: Foetal haemoglobin distribution according to age among Hb SS

References

1. Clarke GM and Higgins TN. Laboratory Investigation of Haemoglobinopathies and Thalassemias: Review and Update. *Clinical Chemistry*.2000; 46(8B):1284 -1290. **PubMed** | **Google Scholar**
2. Bain BJ. Haemoglobinopathy diagnosis: Algorithms, lessons and pitfalls. *Blood Reviews*. 2011; 25(5):205-213. **PubMed** | **Google Scholar**
3. Angastiniotis, Modell B, Englezos P, Boulyjenkov V. Prevention and control of haemoglobinopathies. *Bull World Health Organ*. 1995; 73(3):375-386. **PubMed** | **Google Scholar**
4. World Health Organisation. Sickle cell disease in the African Region: Current situation and the way forward. *WHO Africa Regional Report*. 2006; AFR/RC/56/17. **PubMed** | **Google Scholar**
5. Omotade OO, Kayode CM, Falade SL, Ikpeme S, et al. Routine screening for sickle cell haemoglobinopathy by electrophoresis in an infant welfare clinic. *West African Journal of Medicine*. 1998; 17(2):91-94. **PubMed** | **Google Scholar**
6. Wajcman H, Moradkhani K. Abnormal haemoglobins: detection and characterization. *Indian J Med Res*. 2011; 134(4): 538-54. **PubMed** | **Google Scholar**
7. Mosca A, Paleari R, Ivaldi G, Galanello R, Giordano PC. The role of haemoglobin A₂ testing in the diagnosis of thalassaemias and related haemoglobinopathies. *J Clin Pathol*. 2009; 62(1):13-1. **PubMed** | **Google Scholar**
8. Dacie JV, Lewis SM, White JM, Marsh GW. Investigation of Abnormal Haemoglobins and Thalassaemia, In *Practical Haematology*. Edited by Dacie JV and Lewis SM, London, Churchill Livingstone. 1991; 227-257. **PubMed** | **Google Scholar**
9. Cajado C, Cerqueira BAV, Couto FD, Moura-Neto JP, et al. TNF-alpha and IL-8: Serum levels and gene polymorphisms (308G>A and 251A>T) are associated with classical biomarkers and medical history in children with sickle cell anaemia. *Cytokine*. 2011; 56(2): 312-317. **PubMed** | **Google Scholar**
10. Omoti CE. Beta thalassaemia traits in Nigerian patients with sickle cell anaemia. *Journal of Biomedical Sciences*. 2005; 4(1):37-43. **PubMed** | **Google Scholar**
11. Akinbami A, Dosunmu A, Adediran A, Oshinaike O, Adebola P, Arogundade O. Haematological values in homozygous sickle cell disease in steady state and haemoglobin phenotypes AA controls in Lagos, Nigeria. *BMC Research Notes*. 2012; 5: 396. **PubMed** | **Google Scholar**

12. Old JM. Screening and genetic diagnosis of haemoglobin disorders. *Blood Reviews*. 2003; 17(1):43-53. **PubMed | Google Scholar**
13. Clark BE, Thein SL. Molecular diagnosis of haemoglobin disorders. *Clinical Laboratory Haematology*. 2004; 26(3):159-176. **PubMed | Google Scholar**
14. Colah RB, Surve R, Sawant P, D'Souza E, Italia K, Phanasgaonkar S, Nadkarni AH, Gorakshakar AC. HPLC Studies in Haemoglobinopathies. *Indian Journal of Pediatrics*. 2007; 74(7): 657-662. **PubMed | Google Scholar**
15. Joutovsky A, Hadzi - Nestic J, Nardi MA. Retention time as a diagnostic tool for haemoglobin variants and haemoglobinopathies: A study of 60,000 samples in a clinical diagnostic laboratory. *Clinical Chemistry*. 2004; 50(10): 1736-1747. **PubMed | Google Scholar**
16. Suh DD, Krau JS, Bures K. Influence of haemoglobin S adducts on haemoglobin A2 quantification by HPLC. *Clinical Chemistry*. 1996; 42(7):1113-1114. **PubMed | Google Scholar**
17. Giordano PC. Strategies for basic laboratory diagnostics of the haemoglobinopathies in multi-ethnic societies: interpretation of results and pitfalls. *Inter J of Lab Haematology*. 2013; 35(5): 465-479. **PubMed | Google Scholar**
18. Tshilolo L, Summa V, Gregorj C, Kinsiamia C, Bazebozo JA, Avvisati G, Labie D. Foetal Haemoglobin, Erythrocytes Containing Foetal Haemoglobin, and Hematological Features in Congolese Patients with Sickle Cell Anaemia. Hindawi Publishing Corporation: Anaemia. 2012; Article ID 105349:1-7. **PubMed | Google Scholar**
19. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastian P, Chui DHK, Steinberg MH. Foetal haemoglobin in sickle cell anaemia. *Blood*. 2011; 118(1):19-27. **PubMed | Google Scholar**
20. Steinberg MH. Genetic etiologies for phenotypic diversity in sickle cell anaemia. *Scientific World Journal*. 2009; 9: 46-67.. **PubMed | Google Scholar**
21. Akanni EO, Oseni BS, Bamisaye EO, Raji AA, Mewoyeka OO, Hassan RO. Haemoglobin F level in different haemoglobin variants. *Korean Journal of Hematology*. 2011; 46(2):118-122. **PubMed | Google Scholar**
22. Isah IZ, Udomah FP, Erhabor O, Aghedo F, Uko EK, Okwesili AN, et al. Foetal haemoglobin levels in sickle cell disease patients in Sokoto, Nigeria. *British Journal of Medical and Health Sciences*. 2013; 1(6):36-47. **PubMed | Google Scholar**
23. Enosolease ME, Ejele OA, Awodu OA. The influence of foetal haemoglobin on the frequency of vaso-occlusive crisis in sickle cell anaemia patients. *Niger Postgrad Med J*. 2005; 12(2): 102-105. **PubMed | Google Scholar**
24. Kotila TR, Fawole OI, Shokunbi WA. Haemoglobin F and clinical severity of sickle cell anaemia among Nigerian adults. *African Journal of Medicine and Medical Science*. 2000; 29(3-4):229-231. **PubMed | Google Scholar**
25. Fatunde OJ, Scott-Emuakpor AB. Haemoglobin F and A2 in Nigerian children with sickle cell anaemia. *J Trop Pediatr*. 1993; 39(4): 251-252. **PubMed | Google Scholar**
26. El-Hazmi MAF. Clinical and Haematological Diversity of Sickle cell disease in Saudi Children. *J Trop Pediatr*. 1992; 38(3):106-112. **PubMed | Google Scholar**
27. Mouele R, Galacteros F, Feingold J. Haemoglobin F (HbF) levels in sickle-cell anaemia patients homozygous for the Bantu haplotype. *Eur J Haematol*. 1999; 63(2): 136-137. **PubMed | Google Scholar**
28. Falusi AG, Esan GJF. Foetal haemoglobin in sickle cell anaemia in Nigerians. *Afr J Med Sci*. 1989; 18(2): 145-149. **PubMed | Google Scholar**
29. Steinberg MH, Hsu H, Nagel RL, Milner PF, Adams JG, Benjamin L, et al. Gender and haplotype effects upon hematological manifestations of adult sickle cell anaemia. *Am J Hematol*. 1995; 48(3): 175-181. **PubMed | Google Scholar**
30. Olatunji PO. Sickle cell disease in developing countries: magnitude and challenges. *Postgrad Doc Afr*. 2002; 25(3): 61-64. **PubMed | Google Scholar**
31. Mpalampa L, Ndugwa CM, Ddungu H, Idro R. Foetal haemoglobin and disease severity in sickle cell anaemia patients in Kampala, Uganda. *BMC Blood Disorders*. 2012; 12:11. **PubMed | Google Scholar**
32. Gallanello R, Origa R. Beta-thalassaemia. *Orphanet J of Rare diseases*. 2010; 5:11. **PubMed | Google Scholar**
33. Watson-Williams EJ. Hereditary persistence of foetal haemoglobin and thalassaemia in Nigerians, In: Abnormal haemoglobins in Africa: a c l o m s symposium. Oxford: Blackwell Scientific Publications. 1985; 2.
34. Kotila TR, Adeyemo AA, Mewoyeka OO, Shokunbi WA. Beta thalassaemia trait in Western Nigeria. *Africa Health Sc*. 2009; 9(1):46-48. **PubMed | Google Scholar**
35. Mockenhaupt FP, Falusi AG, May J, Ademowo OG, Olumese PE, Meyer CG, Bienzle U. The contribution of α -thalassaemia to anaemia in a Nigerian population exposed to intense malaria transmission. *Tropical Med and Int Health*. 1999; 4(4):302-307. **PubMed | Google Scholar**
36. Franklin K, Opoku-Okrah C, Obiri-Danso K, Owiredun WKBA, Annan A. The effect of alpha (+) thalassaemia on P; falciparum malaria parasitaemia in children attending Komfo Anokye teaching hospital. *Inter Journal of Biomed Lab Sc*. 2011; 1(1):7-14. **PubMed | Google Scholar**
37. Mockenhaupt FP, Ehrhardt S, Gellert S, Otchwemah RN, Dietz E, Anemana SD, Bienzle U. α -thalassaemia protects African Children from Severe Malaria. *Blood*. 2004; 104 (7): 2003-2006. **PubMed | Google Scholar**

	SS (158)	Sβ-Thal traits (19)	SC (2)	SD-Punjab (1)
Hb F (%)	8.05±5.07	6.03±5.20	0.45±0.07	-
Hb A₂ (%)	3.76±2.53	5.14±1.27 ^a	4.30±2.40	3.3
Hb S (%)	82.90±7.69	84.13±6.94	49.80±1.98 ^{ab}	39.5
Hb (g/dL)	7.35±0.95	6.76±1.25	8.80±0.85 ^{ab}	10.5
PCV (%)	22.17±3.13	21.72±4.04	28.50±3.54 ^{ab}	25
MCV (fL)	79.17±8.05	69.68±5.32 ^c	67.3±6.08	80.9
MCH (pg)	28.42±2.61	21.59±1.71 ^c	22.45±1.48 ^a	23.10
MCHC (g/dL)	32.57±1.37	28.18±1.03 ^c	29.00±0.42 ^a	28.60

a: $P < 0.05$ compared to Hb SS group. b: $P < 0.05$ when compared to Sβ thal traits.
c: $P < 0.001$ compared to Hb SS group.

	Sex	Hb SS	p-value	Hb Sβ-Thal	p-value
Hb F	M	7.63±4.80	0.02	5.68±5.80	0.63
	F	9.55±5.09		6.78±3.87	
Hb A₂	M	3.14±1.89	0.02	5.18±1.36	0.81
	F	4.13±3.37		5.05±1.13	

		≤5	6-10	11-15
Hb F	HbSS	9.23±5.3	7.71±4.6	7.82±5.0
	Sβ-thal	9.99±6.9	3.94±1.9*	3.63±1.8*
Hb A₂	HbSS	3.29±2.7	3.78±2.6	3.60±2.6
	Sβ-thal	5.80±1.4	4.93±1.2	4.56±0.9

* $P < 0.05$.

Age	Hb F				P-value
	0-2	2-9.9	10-19.9	≥20	
≤5	4 (2.6%)	37 (24.3%)	21 (13.8%)	3 (2.0%)	X ² =2.265 df = 6 p-value=0.894
6-10	4 (2.6%)	38 (25%)	14 (9.2%)	1 (0.7%)	
11-15	2 (1.3%)	20 (13.2%)	7 (46%)	1 (0.7)	